Beaver Run Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2009



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Drug Discovery for Protozoan Parasites (D2)


Organizer(s) Dennis E. Kyle, Michael A.J. Ferguson and Susan Charman
March 22—26, 2009
Beaver Run Resort • Breckenridge, Colorado USA
Abstract Deadline: Nov 24, 2008
Late Abstract Deadline: Dec 22, 2008
Scholarship Deadline: Nov 24, 2008
Early Registration Deadline: Jan 22, 2009

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation

Summary of Meeting:
The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification and validation of new targets, chemical biology and medicinal chemistry approaches to characterize new compounds, novel screening techniques to identify new chemotypes, mechanisms of drug resistance, and cutting edge strategies to progress new drug candidates into clinical trials. The objectives of this meeting are to discuss current methods to identify and validate new drug targets and to screen libraries of compounds to discover novel chemotypes; assess the potential for chemical biology and medicinal chemistry to optimize compounds that are specific and avoid resistance mechanisms; and identify critical paths for compound progression and to discuss the utility of key models for assessing preclinical drug leads.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 22

15:00—19:30
Registration

Foyer
18:30—19:30
Refreshments

Foyer
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Peak 5
William N. Charman, Monash University, Australia
Drug Discovery for Protozoan Parasites – The Essential P’s


MONDAY, MARCH 23

07:00—08:00
Breakfast

Peaks 1-4
08:00—11:15
Target Identification and Validation
Meeting has ended...abstracts no longer viewable online.

Peak 5
* Dennis E. Kyle, University of South Florida, USA

John H. Adams, University of South Florida College of Public Health, COPH, USA
Validation of Blood Stage Targets for Malaria Drug Discovery

Lizbeth Hedstrom, Brandeis University, USA
Targeting a Prokaryotic Protein in Eukaryotic Parasite

Michael A.J. Ferguson, University of Dundee, UK
Glycoprotein Biosynthesis in Trypanosoma brucei: Host/Parasite Differences and Therapeutic Potential

Andrew Hopkins, University of Dundee, UK
An Informatics-Based Approach to Target Identification

Meg Phillips, University of Texas Southwestern Medical Center, USA
Short Talk: Structure Function Analysis of Species Specificity in Malarial Dihydroorotate Dehydrogenases

11:15—11:30
Q & A Session
Meeting has ended...abstracts no longer viewable online.

Peak 5
Martin John Rogers, NIAID, National Institutes of Health, USA
Update on the New NIH Stimulus Grants

09:20—09:40
Coffee Break

Foyer
11:15
On Own for Lunch

11:15—13:00
Poster Setup

Peaks 1-4
13:00—22:00
Poster Viewing

Peaks 1-4
14:30—16:30
Workshop 1: Target Validation: Myths and Reality

Peak 5
* Michael A.J. Ferguson, University of Dundee, UK

Jeremy N. Burrows, Medicines for Malaria Venture, Switzerland

Michael A.J. Ferguson, University of Dundee, UK

James Morris, Clemson University, USA

John H. Adams, University of South Florida College of Public Health, COPH, USA

Babu Tekwani, University of Mississippi School of Pharmacy, USA

16:30—17:00
Coffee Available

Foyer
17:00—19:00
Chemical Biology
Meeting has ended...abstracts no longer viewable online.

Peak 5
* Michael A.J. Ferguson, University of Dundee, UK

Leann M. Tilley, University of Melbourne, Australia
The Digestive Vacuole as an Antimalarial Drug Target

Pradipsinh K. Rathod, University of Washington, USA
Novel Mechanisms Underlying Antifolate Drug Selectivity

Timothy A.J. Haystead, Duke University, USA
Chemoproteomics of the Malaria Purinome

Amy K. Wernimont, University of Toronto, Structural Genomics Consortium, Canada
Short Talk: Structural Analyses and Chemical Biology – Targeting the Kinome of Apicomplexan Parasites

19:00—20:00
Social Hour with Lite Bites

Peaks 1-4
19:30—22:00
Poster Session 1

Peaks 1-4

TUESDAY, MARCH 24

07:00—08:00
Breakfast

Peaks 1-4
08:00—11:15
Compounds
Meeting has ended...abstracts no longer viewable online.

Peak 5
* Susan A. Charman, Monash University, Australia

Dominique Mazier, Université Pierre et Marie Curie, France
Novel Approaches for the Identification of Molecules Active on the Hepatic Stages of Malaria

Karl A. Werbovetz, Ohio State University, USA
Arylimidamides as New Antileishmanial Drug Candidates

Paul M. O'Neill, University of Liverpool, UK
Novel Strategies for Antimalarial Chemotherapy and Candidate Selection of a Novel 1,2,4,5-Tetraoxane with Antimalarial Properties Superior to the Semi-Synthetic Artemisinins

Robert Don, Drugs for Neglected Diseases Initiative, Switzerland
The Drugs for Neglected Diseases Initiative – A Product Development Partnership Developing New Drugs for Neglected Tropical Infectious Diseases

Robert H. Barker, Genzyme Corp, USA
Short Talk: A Medicinal Chemistry Program for the Discovery of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Antimalarial Activity

Michael H. Gelb, University of Washington, USA
Short Talk: Lanosterol 14alpha-Demethylase Inhibitors as Anti-Chagas Disease Drug Candidates

09:20—09:40
Coffee Break

Foyer
11:15
On Own for Lunch

11:15—13:00
Poster Setup

Peaks 1-4
13:00—22:00
Poster Viewing

Peaks 1-4
16:30—17:00
Coffee Available

Foyer
17:00—19:00
Screening
Meeting has ended...abstracts no longer viewable online.

Peak 5
* Karl A. Werbovetz, Ohio State University, USA

John S. Lazo, University of Pittsburgh, USA
High Throughput and High Content Screens for Agents Targeting Neglected Diseases

Ronald J. Quinn, Griffith University, Australia
High Throughput Screening of Natural Products

Julie Ann Frearson, University of Dundee, UK
Hit Discovery for HAT; Molecular Target versus Phenotypic Strategies

Rafaela Salgado Ferreira, São Carlos Physics Institute, Brazil
Short Talk: Successes and Failures in using Virtual Screening to Predict the Results of a High Throughput Screen Against Cruzain

19:00—20:00
Social Hour with Lite Bites

Peaks 1-4
19:30—22:00
Poster Session 2

Peaks 1-4

WEDNESDAY, MARCH 25

07:00—08:00
Breakfast

Peaks 1-4
08:00—11:15
Drug Resistance
Meeting has ended...abstracts no longer viewable online.

Peak 5
* Pradipsinh K. Rathod, University of Washington, USA

Rentala Madhubala, Jawaharlal Nehru University, India
Identification of Potential Biomarkers for Antimony Susceptibility / Resistance in L. donovani

Ric N. Price, Menzies School of Health Research, Australia
Drug Resistance in Vivax Malaria

Arjen M. Dondorp, Wellcome Trust-Mahidol University, Thailand
Susceptibility to Artesunate of Plasmodium falciparum in Southeast Asia

Dennis E. Kyle, University of South Florida, USA
Discovery of Antimalarial Drug Combinations to Combat Drug Resistance

Maria Gonzalez-Pons, University of Puerto Rico School of Medicine, USA
Short Talk: Disruption of the Multidrug Resistance Associated Protein (pbmrp) Gene in Plasmodium berghei

09:20—09:40
Coffee Break

Foyer
11:15
On Own for Lunch

14:30—16:30
Workshop 2: Drug Discovery in Academia

Peak 5
* Susan A. Charman, Monash University, Australia

Ian C. Bathurst, Medicines for Malaria Ventures, Switzerland

Robert Don, Drugs for Neglected Diseases Initiative, Switzerland

Ken Duncan, Bill & Melinda Gates Foundation, USA

S A. Ward, University of Liverpool, UK

R. Kip Guy, St. Jude Children's Research Hospital, USA

William N. Charman, Monash University, Australia

16:30—17:00
Coffee Available

Foyer
17:00—19:00
Preclinical Progression
Meeting has ended...abstracts no longer viewable online.

Peak 5
* Michael H. Gelb, University of Washington, USA

R. Kip Guy, St. Jude Children's Research Hospital, USA
Early Lead Optimization for a Novel Series of Antimalarials

Susan A. Charman, Monash University, Australia
ADME Lead Optimization: Application to a Novel Antimalarial Drug Discovery Program

Reto Brun, Swiss Tropical Institute, Switzerland
Pros and Cons of Rodent Models for Malaria and HAT

Robert T. Jacobs, Anacor Pharmaceuticals, Inc., USA
Short Talk: Novel Oxaborole 6-Carboxamides Demonstrate Potential for Treatment of CNS-Stage Human African Trypanosomiasis

19:00—20:00
Social Hour with Lite Bites

Peaks 1-4
20:00—23:00
Entertainment

Peaks 1-4

THURSDAY, MARCH 26

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge additional support for this conference from:

Bill & Melinda Gates Foundation Scynexis, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Cell Press

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676